Key result
Women with new-onset atrial fibrillation were half as likely to receive warfarin as older men, but when treated with warfarin, they were 3.35 times more likely to experience a major bleed.
Why the study?
Are there sex-related differences in presentation, treatment, and outcomes in patients with new-onset atrial fibrillation?
Population
899 patients presenting with first ECG-confirmed diagnosis of new-onset atrial fibrillation
Comparison
Female sex vs Male sex
Design
Cohort
Follow-up
4.14+/-1.39 years
Authors
Discussion
Loading...
Member takes
Implication
Heightened bleeding risk with warfarin in women with new-onset AF warrants monitoring; leaves open optimal sex-specific anticoagulation strategies.
Study Design
Type
Observational (n=899)
Multicenter
Yes
Structured PICO
Are there sex-related differences in presentation, treatment, and outcomes in patients with new-onset atrial fibrillation?
P
Population
899 patients (339 women, 560 men) presenting with first ECG-confirmed diagnosis of new-onset atrial fibrillation
I
Intervention
Female sex (observational analysis of sex differences)
C
Comparator
Male sex
O
Outcome
Sex-related differences in presentation, treatment (anticoagulant use), and outcome (major bleeding)safety
Main Result
Effect estimate: RR 3.35
Cite This Study
Humphries et al. (2001) conducted an observational in New-onset atrial fibrillation (n=899). Female sex vs. Male sex was evaluated on Major bleed (among patients on warfarin) (RR 3.35). Women with new-onset atrial fibrillation were half as likely to receive warfarin as older men, but when treated with warfarin, they were 3.35 times more likely to experience a major bleed.